Tag Archives: Lowers

Stem Cell Therapy Lowers Heart Failure Risk Following Heart Attack

Posted on by
Reply

Mesenchymal stem cells tagged with fluorescent markers

Vusivkova/Shutterstock

The largest trial conducted so far indicated that individuals who received a stem cell infusion right after a heart attack had a lower risk of developing heart failure compared to those who underwent standard treatment. This finding offers compelling evidence that stem cells may aid in the heart’s self-repair mechanisms.

Following a heart attack, the heart muscle sustains permanent damage and weakness, rendering the organ unable to adequately pump blood to meet the body’s needs, frequently resulting in heart failure. Presently, the only available treatments are heart transplants or pumps that can restore heart function.

To explore solutions, researchers turned to stem cells, which possess the remarkable capability to transform into various cell types. Nonetheless, prior studies evaluating their application post-heart attack have yielded inconsistent results. A 2020 study with 375 participants showed that bone marrow-derived cells, which include stem cells that evolve into blood cells, did not notably decrease mortality compared to standard therapies such as cardiac rehabilitation and medications aimed at lowering blood pressure, preventing blood clots, and managing cholesterol levels.

Armin Attar and colleagues from Shiraz University in Iran explored a different strategy. They employed mesenchymal stem cells capable of differentiating into structural cells such as cartilage and adipose tissue. These stem cells are also known to release substances that mitigate inflammation and promote tissue regeneration.

The researchers collected mesenchymal stem cells from umbilical cord blood and administered them into the hearts of 136 patients within three to seven days following their first heart attack. While these stem cells can also be extracted from the individual’s own adipose or bone tissue, the cultivation process can take up to a month. By utilizing umbilical cord blood samples, the team can provide treatments more swiftly and potentially enhance their efficacy, Attar explained. Another group of 260 participants received standard post-heart attack treatments.

After three years, individuals who received the stem cell therapy were, on average, 57% less likely to develop heart failure and 78% less likely to be hospitalized for heart failure compared to those receiving standard treatment. Furthermore, they exhibited significant improvements in cardiac function, suggesting that the therapy aids in the regeneration of heart tissue post-injury.

“This represents a significant advancement,” Attar remarked. Although the therapy did not lower mortality risk during the study period, the reduction in hospitalizations is still significant, according to Hina Chowdhury from the Icahn School of Medicine at Mount Sinai in New York. “Heart failure is the predominant cause of hospital admissions in the U.S.,” she pointed out.

However, it should be noted that 80% of participants were male, leading Chaudhry to caution that it is uncertain how the therapy would affect women, who are more prone to heart failure post-heart attack. Attar’s team did not observe any gender differences in a separate analysis. This study was also restricted to young adults, with all participants aged between 18 and 65. “It’s beneficial to see distinctions among age groups, as younger individuals typically have enhanced regenerative abilities and recover better from cardiac injuries,” Chaudhry noted.

This research provides the most robust evidence to date that stem cells can aid in restoring heart function post-heart attack. Nevertheless, this treatment does not fully heal the heart. “There is no medication or treatment that can replace lost heart muscle cells,” Chaudhry emphasized. Still, she added, “This ongoing work is expanding our understanding of the heart’s regeneration process and how to achieve it.”

Topics:

Source: www.newscientist.com

2-Inch Inhaler Lowers Asthma Attacks in Young Children

Posted on by
Reply

Combination Asthma Inhalers are likely the best treatment choice for individuals of all ages

sbdigit/getty images

Inhalers, providing both immediate and long-term relief, are already the standard treatment for mild asthma among individuals over 12 in the UK, US, and other regions. A recent study involving nearly 400 children in New Zealand indicates these inhalers are even more effective for younger kids, nearly halving the number of asthma attacks.

Team members have stated that whether these findings will prompt changes in national and international guidelines remains uncertain. Andy Bush from Imperial College London asserts that the evidence is compelling. “If you’re a child with asthma, I have those combinations,” he remarks.

The traditional treatment for mild asthma involved an inhaler containing salbutamol, which relaxes airway muscles for about 3-4 hours. These “rescue” inhalers were to be used as needed.

If the rescue inhaler was inadequate, patients were provided with a separate inhaler containing steroids that help reduce inflammation caused by asthma. These “preventive” inhalers required regular usage to ensure protective benefits. Bush comments, “Previously, I had to take inhaled steroids twice a day for them to work, but it’s now evident that’s not always necessary.”

Studies involving teenagers and adults have indicated that combination inhalers outperform the previous treatment method, even when used on an as-needed basis. The steroids found in these combination inhalers are budesonide, while the reliever is formoterol, which acts similarly to salbutamol but lasts for 12 hours.

Concerns regarding the use of combination inhalers by children have emerged due to potential growth effects from steroid components; however, the latest research showed no negative impact during the trial period. The study involved 360 children randomly assigned to use either budesonide-fluticasone or steroid fluticasone twice daily, with additional relief administered as required during severe asthma episodes.

In other studies, the use of combination inhalers led to a decrease in overall steroid intake, according to Bush. This is because using the inhalers on an as-needed basis causes the dosage of inhaled steroids to adapt according to symptom severity. Fewer attacks mean fewer individuals need to “step up” to the combination inhaler two times daily or rely on steroid pills.

topic:

Source: www.newscientist.com

Gastric Bypass Surgery Potentially Lowers Intestinal Cancer Risk

Posted on by
Reply

Gastric bypass surgery is primarily utilized for weight loss, but it may provide other advantages

Portra/Getty Images

A widely recognized form of weight loss surgery may lower the risk of colorectal cancer by changing the levels of bile acids in the bloodstream. These findings could pave the way for new bowel cancer treatments.

During gastric bypass surgery, the stomach is surgically altered to create a small upper pouch and a larger lower pouch. The small intestine is then connected to the upper pouch, allowing food and digestive juices to bypass most of the upper stomach and small intestine. Post-surgery, patients often feel fuller and experience quicker weight loss.

Earlier research indicated that this procedure is associated with a decreased risk of colorectal cancer; however, the underlying reasons remained unclear. To investigate further, Rebecca Kesselling of the University of Freiburg, Germany, and her team fed mice a high-fat diet until they reached approximately 50% of their starting weight. They then performed a partial gastric bypass on some of the mice, while the remaining mice underwent a sham surgery that did not alter their digestive systems.

To isolate the weight-loss effects of gastric bypass surgery, the team grouped the gastric bypass mice alongside half of the sham-operated mice. Over six weeks, the gastric bypass mice lost about 20% of their body weight on average.

Subsequently, the researchers implanted colorectal cancer cells into the colons of the mice. After an additional six weeks, it was observed that colon tumors in the gastric bypass mice were two-thirds smaller than those in the mice that either continued gaining weight or lost weight solely through diet.

Additionally, cancer spread to the liver was seen in only one out of twenty gastric bypass mice, while it occurred in most of the sham-operated mice.

“Both sham groups exhibited similar tumor levels, but weight loss alone could not account for the lower cancer risk, suggesting that gastric bypass involves additional factors,” Kesselling explains.

The researchers speculated that this might be attributed to alterations in bile acids, which are compounds that aid in fat digestion. These molecules are typically produced by the liver, move through the gallbladder, stomach, and small intestine, and then return to the liver via the bloodstream.

“Bile acids are reintroduced into the small intestine during bypass surgery,” Kesselling states, implying that this process may lead to variations in intestinal bacteria that chemically modify these molecules.

The mice that underwent gastric bypass surgery displayed lower levels of specific bile acids, known as primary bile acids, in both their colon and bloodstream compared to the sham group.

To further explore whether changes in bile acids influenced cancer risk, the team conducted a similar experiment with another group of mice. Instead of gastric bypass, these mice had surgery that redirected bile acids to the latter part of the small intestine without altering the stomach.

Significantly, the team noted that this surgery also lowered primary bile acid levels in the bloodstream and decreased the size and spread of colorectal tumors as effectively as gastric bypass surgery. This was supported by an additional experiment, where they identified that primary bile acids promote the growth of colorectal cancer cells in laboratory settings.

The results indicate that focusing on primary bile acids may hold promise for cancer treatment. “We might be able to leverage various oral medications designed to reduce these bile acids to replicate some of the advantageous effects of gastric bypass surgery,” notes Vance Albaf from Louisiana State University.

Topic:

Source: www.newscientist.com

Revolutionary Breakthrough: One Dose of New Cholesterol Treatment Lowers Levels by 69%

Posted on by
Reply

The innovative drug Single Shot can reduce cholesterol levels by as much as 69%. Preliminary findings from clinical trials have not yet undergone peer review.

Known as Verve-102, this treatment could revolutionize heart attack prevention and significantly lower LDL cholesterol levels (often referred to as “bad” cholesterol) with a single injection.

While statins can achieve similar cholesterol reductions, they typically require daily administration.

“This is the future,” stated Professor Riyaz Patel, an academic from the University of London and a doctor at Barts Health NHS Trust involved in the trial – BBC Science Focus.

“This is not a fantasy; it’s reality. We are actively implementing it. I was providing this treatment to my patient during the exam.”

Unlike statins, which gradually lower cholesterol, Verve-102 aims for a one-time alteration by “turning off” a specific gene called PCSK9 in the liver. This gene is crucial in managing the levels of LDL cholesterol that the liver can detect and eliminate from the bloodstream.

In simpler terms, a reduction in PCSK9 means less LDL in the bloodstream.

“The results are stunning,” Patel remarked. “This drug disables a small segment of your DNA, and your LDL cholesterol will be permanently 50% lower thereafter. That’s a game-changer!”

Cholesterol builds up in blood vessel walls, leading to plaque formation that can obstruct blood flow.

Elevated LDL cholesterol levels heighten the risk of this buildup, prompting millions (over 40 million in the US and over 7 million in the UK) to take daily medications like statins for cholesterol management.

The VERVE-102 clinical trial included 14 participants with familial hypercholesterolemia, a genetic disorder that heightens the risk of heart disease, heart attacks, and strokes due to extremely high LDL cholesterol levels.

Initial outcomes from Verve-102 injections show that all participants reacted positively to the treatment with no severe side effects.

Responses varied by dosage. The lowest dose group experienced an average LDL reduction of 21%, while the intermediate group showed a 41% reduction, and the high-dose group saw a 53% reduction.

Remarkably, one individual in the high-dose group achieved a 69% reduction in LDL cholesterol after receiving Verve-102.

Dr. Eugene Braunwald, a distinguished medical professor and Hershey’s professor of medicine at Harvard Medical School who did not take part in the study, noted that the preliminary data is “promising” and indicates “the potential for a new era in cardiovascular disease treatment.”

Verve is actively recruiting participants for further stages of clinical trials involving even higher Verve-102 doses in the UK, Canada, Israel, Australia, and New Zealand. The final results are expected to be revealed in the latter half of 2025.

Read more:

About our experts

Professor Riyaz Patel is a consultant cardiologist and clinical academic scholar at University College London (UCL) and Barts Health NHS Trust. He is a fully funded clinician scientist with the British Heart Foundation and serves as a professor of cardiology at UCL, where he investigates the causes of heart disease, focusing on cardiovascular risks and the genetics of coronary heart disease. He has established and led new cardiovascular prevention services at Barts Heart Center.

Source: www.sciencefocus.com

Study finds that consuming more dark chocolate, instead of milk, lowers risk of developing type 2 diabetes

Posted on by
Reply

A long-term US study found that consuming at least 5 servings of dark chocolate per week (1 serving equals a standard chocolate bar/pack or 1 oz) was associated with lower risk of type 2 diabetes compared to infrequent consumption. However, increased milk chocolate intake was associated with increased weight gain.

Consuming dark chocolate instead of milk chocolate may lower your risk of type 2 diabetes. Image credit: Sci.News.

The global prevalence of type 2 diabetes has increased significantly over the past few decades, with an estimated 463 million people affected worldwide in 2019 and projected to rise to 700 million by 2045. I am.

Type 2 diabetes is a multifactorial disease characterized by insulin resistance and impaired insulin secretion, which can lead to a number of serious complications, including cardiovascular disease, kidney failure, and vision loss.

A series of studies has highlighted the importance of lifestyle factors, such as a healthy diet, in the prevention and management of type 2 diabetes.

Higher total dietary flavonoid intake, as well as specific flavonoid subclasses, is associated with a lower risk of type 2 diabetes.

Randomized controlled trials have shown that these flavonoids exert antioxidant, anti-inflammatory, and vasodilatory effects that may benefit cardiometabolism and reduce the risk of type 2 diabetes, but the data are inconsistent. It wasn’t.

chocolate made from beans cacao tree (Theobroma cacao)one of the foods with the highest flavanol content and a popular snack around the world.

However, the association between chocolate intake and risk of type 2 diabetes remains controversial due to inconsistent results obtained in observational studies.

For new research, Liu Binkai Researchers at Harvard University's T.H. Chan School of Public Health combined data from three longitudinal U.S. observational studies of female nurses and male health care workers who had no history of diabetes, heart disease, or cancer at the time of recruitment. .

They investigated type 2 diabetes and total chocolate intake in 192,208 participants and 111,654 participants over an average 25-year monitoring period using food frequency questionnaires completed every 4 years. We analyzed the relationship between chocolate subtype (dark and milk) intake.

Because weight change strongly predicts type 2 diabetes risk, the researchers also used these food questionnaires to assess participants' total energy intake.

In the overall chocolate analysis, 18,862 people developed type 2 diabetes. After adjusting for personal, lifestyle, and dietary risk factors, the authors found that people who ate all types of chocolate at least five times a week were more likely to develop type 2 diabetes than those who ate little or no chocolate. We found that the incidence was significantly lower by 10%. .

In the chocolate subtype analysis, 4,771 people developed type 2 diabetes. After adjusting for the same risk factors, those who ate dark chocolate at least five times a week had a 21% significantly lower risk of type 2 diabetes, but there was no significant association with milk chocolate intake. was not found.

Researchers also found that each additional weekly intake of dark chocolate reduced the risk of type 2 diabetes by 3% (dose-response effect).

Increased milk intake was associated with long-term weight gain, but dark chocolate intake was not.

Dark chocolate has similar levels of energy and saturated fat as milk chocolate, but the high levels of flavanols found in dark chocolate reduce the risk of saturated fat and sugar for weight gain and other cardiometabolic diseases such as diabetes. may offset the effects of

“Increased consumption of dark chocolate, but not milk, was associated with a lower risk of type 2 diabetes,” the scientists said.

“Increased milk intake was associated with long-term weight gain, but dark chocolate intake was not.”

“Further randomized controlled trials are needed to replicate these findings and further investigate the mechanisms.”

of study What was posted this week BMJ.

_____

Liu Binkai others. 2024. Chocolate intake and risk of type 2 diabetes: A prospective cohort study. BMJ 387: e078386;doi: 10.1136/bmj-2023-078386

Source: www.sci.news